SCHEMBL8934495

SCHEMBL8934495

Cc1cc2c(=O)[nH]cc(C)c2cc1OC1CCN(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.42
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
PARP1 P09874 1/20 0.39
HRH1 P35367 3/20 0.37
CCR3 P51677 3/20 0.37
BRD4 O60885 2/20 0.36
KCNH2 Q12809 1/20 0.36
KDM4E B2RXH2 2/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NSD2 O96028 1/20 0.34
TDO2 P48775 1/20 0.34
PLG P00747 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230367 0.94 ROCK1 (0.41) ROCK1MAOAMAOBPARP1HRH1
SCHEMBL8935395 0.87 PARP1 (0.43) ROCK1MAOAMAOBPARP1HRH1
SCHEMBL8935441 0.86 HRH1 (0.41) ROCK1MAOAMAOBPARP1HRH1
SCHEMBL8934576 0.86 KDM4E (0.43) ROCK1MAOAMAOBPARP1HRH1
SCHEMBL8938601 0.85 ROCK1 (0.50) ROCK1HRH1CCR3BRD4KDM4E
SCHEMBL8935399 0.85 MAOA (0.46) ROCK1MAOAMAOBPARP1HRH1
SCHEMBL8935558 0.84 ROCK1 (0.41) ROCK1HRH1CCR3KCNH2KDM4E
SCHEMBL8935499 0.84 HRH1 (0.41) ROCK1HRH1CCR3KCNH2LMNA
SCHEMBL8934405 0.84 ROCK1 (0.49) ROCK1PARP1HRH1CCR3
SCHEMBL8935529 0.84 PARP1 (0.44) ROCK1PARP1HRH1CCR3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885MAOA 2633/4885MAOB 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.